Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A treatment algorithm for neuropathic pain.

Mike Namaka1, Colin R Gramlich, Dana Ruhlen

  • 1University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba R3T 2N2, Canada. namakamp@ms.umanitoba.ca

Clinical Therapeutics
|September 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Brain : a journal of neurology·2025
Same author

Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2024
Same author

Neutropaenia complications from Ocrelizumab and Rituximab treatment.

Multiple sclerosis and related disorders·2023
Same author

Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant.

Cytotherapy·2023
Same author

Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis.

Clinical immunology (Orlando, Fla.)·2023
Same author

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

JAMA neurology·2023

This review proposes a treatment algorithm to manage neuropathic pain, guiding clinicians through first-line and second-line drug options. The algorithm aims to optimize therapy and streamline referrals for refractory cases.

Area of Science:

  • Neurology
  • Pharmacology
  • Pain Management

Background:

  • Neuropathic pain stems from sensory neuron damage, causing symptoms like burning and numbness.
  • Neuronal hyperexcitability is a key factor in neuropathic pain.
  • Current treatments may only partially alleviate pain.

Purpose of the Study:

  • To present a treatment algorithm for neuropathic pain.
  • To guide healthcare professionals in adapting treatment to individual patient needs.
  • To optimize the use of available therapeutic options.

Main Methods:

  • A comprehensive literature review of PubMed, MEDLINE, Cochrane, and Toxnet databases.
  • Development of a novel treatment algorithm for neuropathic pain.
  • Inclusion of various drug classes: antidepressants, antiepileptics, topical agents, narcotics, and analgesics.

Related Experiment Videos

Main Results:

  • First-line treatments include antidepressants, antiepileptics, topical agents, and analgesics.
  • If monotherapy fails, second-line agents or combination therapy can be considered.
  • Narcotic analgesics and specialized pain clinic referrals are options for refractory cases.

Conclusions:

  • Neuropathic pain remains challenging to treat effectively.
  • The proposed algorithm provides a framework for personalized pain management.
  • The algorithm aims to improve efficiency in referring patients to specialized pain clinics.